



---

### BERUFLICHER WERDEGANG

07.2020-dato	Co-Chefarzt, Medizinische Universitätsklinik, Kantonsspital Baselland
09.2018-dato	Stv. Leiter Darmkrebszentrum, Kantonsspital Baselland
01.2015-dato	Leiter Gastroenterologie, Kantonsspital Baselland
01.2014 - 01.2015	Leitender Arzt, Gastroenterologie, Medizinische Universitätsklinik, Kantonsspital Baselland
07.2013 - 12.2013	Oberarzt, Gastroenterologie, Medizinische Universitätsklinik, Kantonsspital Baselland
10.2012 - 06.2013	Oberarzt, Gastroenterologie und Hepatologie, Innere Medizin, Stadtspital Triemli, Zürich
07.2011 - 07.2012	Assistenzarzt, Gastroenterologie, Medizinische Universitätsklinik, Kantonsspital Baselland
07.2010 - 06.2011	Assistenzarzt, Gastroenterologie und Hepatologie, Universitätsspital Basel
09.2008 - 06.2010	Forschungsassistent, Abteilung für Gastrointestinale Forschung, Universitätsspital Vall d'Hebron, Barcelona, Spanien
04.2008 - 08.2008	Forschungsassistent, Innere Medizin, Universitätsspital Basel
08.2007 - 03.2008	Assistenzarzt, Medizinische Poliklinik, Universitätsspital Basel
10.2004 - 07.2007	Assistenzarzt, Innere Medizin, Universitätsspital Basel
08.2003 - 08.2004	Assistenzarzt, Chirurgische Klinik, Kantonsspital Baselland
03.2002 - 07.2003	Forschungsassistent, Medizinische Universitätsklinik, Kantonsspital Baselland

---

### AKADEMISCHER WERDEGANG

2015	Venia Docendi (Habilitation) Innere Medizin, speziell Gastroenterologie
2014	Spezialisierung Endoskopische Retrograde Cholangio- Pankreatikographie (ERCP)
2014	Sachverständigung dosisintensives Röntgen
2012	Facharzttitel FMH Gastroenterologie
2009	Facharzttitel FMH Innere Medizin
2007	Dissertation, Medizinische Fakultät, Universität Basel
2001	Eidgenössisches Staatsexamen

## **INSTITUTIONELLE AKTIVITÄTEN**

2019	IBDnet Steering Committee Member
2019	National Representative European Crohn's and Colitis Organization (ECCO)
2018	IBDnet Operational Committee Member

---

## **MITGLIEDSCHAFTEN**

Verbindung der Schweizer Ärztinnen und Ärzte (FMH)

Verein Schweizerischer Assistenz- und Oberärztinnen und -ärzte (VSAO)

Schweizerische Gesellschaft für Gastroenterologie (SGG)

Inflammatory Bowel Disease Net (IBDnet)

European Crohn's and Colitis Organization (ECCO)

Europäische Gesellschaft für Neurogastroenterologie und Motilität (ESNM)

Deutsche Gesellschaft für Neurogastroenterologie und Motilität (DGNM)

Europäische Gesellschaft für Gastrointestinale Endoskopie (ESGE)

European Society of Eosinophilic Esophagitis (EUREOS)

---

## **SPRACHEN**

Deutsch (Muttersprache), Englisch, Französisch, Spanisch

## Scientific Publications

### Peer-Reviewed Articles

1. Sulz MC, **Burri E**, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F. *Treatment Algorithms for Crohn's Disease*. *Digestion* 2020 Mar 13;1-15
2. Wuggenig P, Kaya B, Melhem H, Ayata CK; **Swiss IBD Cohort Investigators**, Hruz P, Sayan AE, Tsumura H, Ito M, Roux J, Niess JH. *Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice*. *Commun Biol*. 2020 Mar 18;3(1):130
3. Serra EG, Schwerd T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C, Travis SP, Satsangi J, Parkes M, Thapar N, Ferry H, Matte JC, Gilmour KC, Wedrychowicz A, Sullivan P, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Baeumler TA, Fulga TA, Karaminejadranjbar M, Ahmed A, Wilson R, Barrett JC, Elkadri A, Griffiths AM; **COLORS in IBD group investigators**; Oxford IBD cohort study investigators; INTERVAL Study; **Swiss IBD cohort investigators**; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, Snapper SB, Shah N, Muise AM, Wilson DC, Uhlig HH, Anderson CA. *Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease*. *Nat Commun*. 2020 Feb 21;11(1):995. doi: 10.1038/s41467-019-14275-y.
4. **Burri E**, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, Rogler G, Zahnd N, Vavricka S. *Position statement on the use of biosimilars in inflammatory bowel disease*. *Swiss Med Wkly*. 2019 Dec 2;149:w20148. doi: 10.4414/smw.2019.20148. eCollection 2019 Dec 2.
5. **Burri E**, Maillard MH, Schoepfer AM, Seibold F, Van Asche G, Riviere P, Laharie D, Manz M. *Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update*. *Digestion* 2020 Jan 16:1-14
6. Cernoch PS, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; **Swiss IBD Cohort Study Group**. *Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study*. *Dig Dis Sci*. 2019 Dec 3
7. Barba E, Sánchez B, **Burri E**, Accarino A, Monclus E, Navazo I, Guarner F, Margolles A, Azpiroz F. *Abdominal distension after eating lettuce: The role of intestinal gas evaluated in vitro and by abdominal CT imaging*. *Neurogastroenterol Motil*. 2019 Aug 11 (epub ahead of print)
8. Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; **Swiss IBD Cohort Investigators**, Wiest R, Stelling J, Macpherson AJ. *Microbial network disturbances in relapsing refractory Crohn's disease*. *Nat Med*. 2019 Jan 21.
9. Tcymbarevich IV, Eloranta JJ, Rossel JB, Obialo N, Spalinger M, Cosin-Roger J, Lang S, Kullak-Ublick GA, Wagner CA, Scharl M, Seuwen K, Ruiz PA, Rogler G, de Vallière C, Misselwitz B; **Swiss IBD Cohort Study Group**. *The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation*. *BMC Gastroenterol*. 2019 Jan 7;19(1):2
10. Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, **Burri E**, Schneider-Yin X, Barman-Aksoezen J, Biedermann L, Scharl M, Zeitz J, Rogler G, Misselwitz B, Sauter M. *The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding*. *United European Gastroenterol J*. 2018 Aug;6(7):1007-1014.
11. Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; **Swiss IBD Cohort Study Group**. *Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study*. *J Crohns Colitis*. 2018 Jun 28;12(7):811-818
12. Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M; **Swiss IBD Cohort Study Group**. *The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort*. *Inflamm Bowel Dis*. 2018 Apr 13. [Epub ahead of print].
13. Lang BM, Biedermann L, van Haften WT, de Vallière C, Schuurmans M, Bègré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N,

# Kantonsspital Baselland

- Misselwitz B; **Swiss IBD Cohort Study Group**. *Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease*. *Aliment Pharmacol Ther*. 2018 Jan;47(1):55-66. Epub 2017 Oct 20.
14. Bendezú RA, Barba E, **Burri E**, Cisternas D, Accarino A, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Colonic content in health and its relation to functional gut symptoms*. *Neurogastroenterol Motil*. 2016 Jun;28(6):849-54. (IF 2.94, Rank 29/74).
  15. Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; **Swiss IBD Cohort Study Group**. *Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease*. *Clin Gastroenterol Hepatol*. 2016 Jun;14(6):829-835.e1. (IF 6.65, Rank 8/74).
  16. Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; **Swiss IBD Cohort Study**. *Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?* *J Crohns Colitis*. 2016 Mar;10(3):269-76. (IF 3.56, Rank 20/74)
  17. Bendezú RA, Barba E, **Burri E**, Cisternas D, Malagelada C, Segui S, Accarino A, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Intestinal gas content and distribution in health and in patients with functional gut symptoms*. *Neurogastroenterol Motil*. 2015 Jun 21 [Epub ahead of print] (IF 2.94, Rank 29/74).
  18. Lehmann FS, **Burri E**, Beglinger C. *The role and utility of faecal markers in IBD*. *Therap Adv Gastroenterol*. 2015 Jan;8(1):23-36. Review.
  19. Barba E\*, **Burri E\***, Accarino A, Cisternas D, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Abdominothoracic mechanisms of functional abdominal distension and correction by biofeedback. \*Equal contributors*. *Gastroenterology*. 2015 Apr;148(4):732-9 (IF 13.93, Rank 1/74).
  20. **Burri E**, Beglinger C, von Felten S, Lehmann FS. *Fecal calprotectin and the Clinical Activity Index are both useful to monitor medical treatment in patients with ulcerative colitis*. *Dig Dis Sci*. 2015 Feb;60(2):485-91. Epub 2014 Oct 26. (IF 2.55, Rank 28/74)
  21. Vavricka SR, Radivojevic S, Manser CN, Frei P, **Burri E**, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. *Addressing current treatment challenges in Crohn's disease in real life: a physician's survey*. *Dig Liver Dis*. 2014 Dec;46(12):1066-71. Epub 2014 Aug 29. (IF 2.89, Rank 28/74)
  22. Barba E, **Burri E**, Accarino A, Malagelada C, Rodriguez-Urrutia A, Soldevilla A, Malagelada JR, Azpiroz F. *Biofeedback-guided control of abdominothoracic muscular activity reduces regurgitation episodes in patients with rumination*. *Clin Gastroenterol Hepatol*. *Clin Gastroenterol Hepatol*. 2015 Jan;13(1):100-6.e1. Epub 2014 Apr 24. (IF 6.65, Rank 8/74).
  23. **Burri E**, Manz M, Schroeder P, Froehlich F, Rossi L, Beglinger C, Lehmann FS. *Diagnostic yield of endoscopy in patients with abdominal complaints: Incremental value of fecal calprotectin on guidelines of appropriateness*. *BMC Gastroenterol*. 2014 Mar 29;14(1):57. Epub 2013 May 23. (IF 2.11, Rank 42/74)
  24. Maillard MH, Bortolotti M, Vader JP, Mottet C, Schoepfer A, Gonvers JJ, Burnand B, Froehlich F, Michetti P, Pittet V; **Swiss IBD Cohort Study Group**. *Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis*. *J Crohns Colitis*. 2014 Aug 1;8(8):825-34 (IF 3.56, Rank 20/74)
  25. **Burri E**, Beglinger C. *The use of fecal calprotectin as a biomarker in gastrointestinal disease*. *Expert Rev Gastroenterol Hepatol*. 2014 Feb;8(2):197-210. Epub 2013 Dec 18 (IF 2.22, Rank 38/74).
  26. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; **Swiss IBD Cohort Study Group**. *Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease*. *Digestion*. 2013;87(3):212-21. Epub 2013 May 23. (IF 1.94, Rank 46/74).
  27. **Burri E**, Cisternas D, Villoria A, Accarino A, Soldevilla A, Eng E, Malagelada JR, Azpiroz F. *Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia*. *Gut*. 2014 Mar;63(3):395-400. Epub 2013 May 4. (IF 10.73, Rank 3/74).
  28. Barba E, Quiroga S, Accarino A, Monclus Lahoya I, Malagelada C, **Burri E**, Malagelada JR, Azpiroz F. *Mechanisms of abdominal distension in severe intestinal dysmotility: abdomino-thoracic response to gut retention*. *Neurogastroenterol Motil*. 2013 Jun;25(6):e389-94. Epub 2013 Apr 22. (IF 2.94, Rank 29/74).

# Kantonsspital Baselland

29. **Burri E**, Schulte F, Muser J, Meier R, Beglinger C. *Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count*. World J Gastroenterol. 2013 Apr 7;19(13):2028-36. (IF 2.55, Rank 34/74).
30. **Burri E**, Cisternas D, Villoria A, Accarino A, Soldevilla A, Eng E, Malagelada JR, Azpiroz F. *Abdominal accommodation induced by meal ingestion: differential responses to gastric and colonic volume loads*. Neurogastroenterol Motil. 2013 Apr;25(4):339-e253. Epub 2013 Jan 29. (IF 2.94, Rank 29/74).
31. **Burri E**, Manz M, Rothen C, Rossi L, Beglinger C, Lehmann FS. *Monoclonal antibody testing for faecal calprotectin is superior to polyclonal testing of faecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort*. Clin Chim Acta. 2013 Feb 1;416:41-7. Epub 2012 Nov 21. (IF 2.85, Rank 6/32).
32. **Burri E**, Hochholzer K, Arenja N, Martin-Braschler H, Kaestner L, Gekeler H, Hatzissaak T, Büttiker M, Fräulin A, Potocki M, Breidhardt T, Reichlin T, Socrates T, Twerenbold R, Mueller C. *B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care*. J Intern Med. 2012 Nov;272(5):504-13. Epub 2012 Jun 12. (IF 6.46, Rank 10/155).
33. **Burri E**, Beglinger C, Lehmann FS. *Monitoring of therapy for inflammatory bowel disease*. Digestion 2012;86 Suppl 1:1-5. Epub 2012 Oct 5 (IF 1.94, Rank 46/74).
34. Klima T, Christ A, Marana I, Kalbermatter S, Uthoff H, **Burri E**, Hartwiger S, Schindler C, Breidhardt T, Marenzi G, Mueller C. *Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial*. Eur Heart J. 2012 Aug;33(16):2071-9. Epub 2012 Jan 19. (IF 14.10, Rank 2/124).S
35. Manz M\*, **Burri E\***, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. *Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study*. BMC Gastroenterol. 2012 Jan 10;12(1):5. \*Equal contributors (IF 2.11, Rank 29/74).
36. **Burri E**, Cisternas D, Villoria A, Accarino A, Soldevilla A, Malagelada JR, Azpiroz F. *Accommodation of the abdomen to its content: integrated abdomino-thoracic response*. Neurogastroenterol Motil. 2012 Apr;24(4):312-e162. Epub 2011 Dec 21. (IF 2.94, Rank 29/74).
37. **Burri E**, Potocki M, Drexler B, Schuetz P, Mebazaa A, Ahlfeld U, Balmelli C, Heinisch C, Noveanu M, Breidhardt T, Schaub N, Reichlin T, Mueller C. *Value of arterial blood gas analysis in patients with acute dyspnea: an observational study*. Crit Care. 2011 Jun 9;15(3):R145. (IF 4.72, Rank 5/27).
38. Villoria A, Azpiroz F, **Burri E**, Cisternas D, Soldevilla A, Malagelada, JR. *Abdomino-phrenic dyssynergia in patients with abdominal bloating and distension*. Am J Gastroenterol. 2011 May;106(5):815-9. (IF 7.75, Rank 7/74).
39. Reichlin T, Potocki M, Breidhardt T, Noveanu M, Hartwiger S, **Burri E**, Klima T, Stelzig C, Laule K, Mebazaa A, Christ M, Mueller C. *Diagnostic and prognostic value of uric acid in patients with acute dyspnea*. Am J Med. 2009 Nov;122(11):1054.e7-1054.e14. (IF 5.12, Rank 14/153).
40. Manz M, **Burri E**, Degen L, Beglinger C, Vavricka SR. *Serum protein electrophoresis: An underused but very useful test*. Digestion. 2009;79(4):203-10. Epub 2009 Apr 9. Review. (IF 1.94, Rank 46/74).
41. **Burri E**, Meier R. *Malnutrition in hospitals - A pilot study*. Praxis (Bern 1994). 2008 Jun 11;97(18):657-63. German.
42. Meier R, **Burri E**, Steuerwald M. *The role of nutrition in diarrhoea syndromes*. Curr Opin Clin Nutr Metab Care. 2003 Sep;6(5):563-7. Review.

## Letters, Invited Commentaries

1. **Burri E**, Beglinger C, Lehmann FS. Reply: To PMID 25344905. Dig Dis Sci. 2015 Apr;60(4):1109-10.
2. **Burri E**, Beglinger C. *Fecal calprotectin testing - the need for better standardization*. Nat Rev Gastroenterol Hepatol 2014 (IF 10.42, Rank 4/74, in press)
3. **Burri E**, Manz M, Rieder S, Beglinger C. *Limited value of fecal calprotectin in patients with liver cirrhosis*. Scand J Gastroenterol. 2011 Dec;46(12):1527-8. (IF 2.16, Rank 40/74).

## Reviews

1. Mariann Szabo, **Burri E**. *Magen und Darm: Sensible Hochleistungsorgane*. Hausarzt Praxis 2019;14(1):2

# Kantonsspital Baselland

2. Ansprenger C, **Burri E**. *Diagnose und Monitoring bei chronisch-entzündlichen Darmerkrankungen*. Therapeutische Umschau (2018), 75(5), 316-328
3. Hitz L, **Burri E**. *Helicobacter pylori. Heute noch ein Problem in der hausärztlichen Praxis?* Der informierte @rzt. 2018;01:16-17.
4. **Burri E**, Beglinger C, Biedermann L, Michetti P, Nydegger A, Schoepfer A, Seibold F, Vavricka S, Rogler G. *Diagnostischer Nutzen von Calprotectin im klinischen Alltag*. Schweiz Med Forum 2016;16(03):68-73
5. **Burri E**. *Blähungen bei funktionellen Darmerkrankungen*. Leading Opinions Innere Medizin 2015;02:40-44.
6. Kraft M, Frischknecht J, Michel J, Fostiropoulos K, **Burri E**, Brosi P, Köberle R, Rosenberg R, Tschopp K. *Oropharyngale 24h-pH-Metrie bei laryngopharyngealem Reflux*. Schweiz Med Forum 2015;15(29-30):684-687.
7. **Burri E**. *Calprotectin im klinischen Alltag*. Leading Opinions Innere Medizin 2014:46-49.
8. **Burri E**, Vavricka SR. *Perianal Crohn's Disease*. Ther Umsch. 2013 Jul;70(7):417-28.
9. **Burri E**, Beglinger C. *Fecal calprotectin - A useful tool in the management of inflammatory bowel disease*. Swiss Medical Weekly. Swiss Med Wkly. 2012 Apr 5;142 (IF 1.82, Rank 50/155).
10. **Burri E**, Meier R. *Ulkuskrankheit - Update 2011*. Swiss Med Forum 2011;11(49):897-906
11. **Burri E**, Beglinger, C. *Diagnostic value of faecal calprotectin in inflammatory bowel disease*. Biochem Med. 2011;21(3):245-53 (IF 1.87, Rank 13/32).

## Book Chapters

1. Christoph A. Maurer and **Emanuel Burri**. *Proximal Rectal Adenocarcinoma*, in Clinical Scenarios in Surgical Oncology, ed. Vijay P. Kathri, 136-139, Philadelphia: Lippincott Williams & Wilkins 2006
2. Christoph A. Maurer and **Emanuel Burri**. *Distal Rectal Adenocarcinoma*, in Clinical Scenarios in Surgical Oncology, ed. Vijay P. Kathri, 140-145, Philadelphia: Lippincott Williams & Wilkins 2006

## Case Reports / Clinical Images

1. **Burri E**, Toia D, Meier R. *Triple pylorus*. Endoscopy 2012;44 Suppl 2 UCTN:E362. Epub 2012 Sept 25. (IF 5.74, Rank 9/74).
2. Vavricka SR, Manz M, **Burri E**. *Trichuris trichiura (Whipworm)*. Clin Gastroenterol Hepatol. 2009 Oct;7(10):A16. Epub 2008 Dec 13. (IF 5.29, Rank 38/72).
3. **Burri E**, Nuesch R, Lugli A, Vavricka S. *Early gastric cancer--or not*. Praxis (Bern 1994). 2008 Dec 17;97(25):1351-5. German.
4. Brendebach S, **Burri E**, Imfeld S, Jacob AL, Zimmerli L. *Non-controllable blood pressure peaks--pheochromocytoma?* Praxis (Bern 1994). 2008 Dec 17;97(25):1357-61. German.
5. **Burri E**, Zulewski H, Nüesch R. *Hyperprolactinemia in a man's world*. Praxis (Bern 1994). 2008 Dec 3;97(24):1295-9. German
6. **Burri E**, Decker M, Eriksson U, Buser P, Hunziker L. *28-year old patient with successfully treated dilatative cardiomyopathy*. Internist (Berl). 2008 Mar;49(3):349-52. German.
7. **Burri E**, Rüegg S, Rutishauser J, Egger SS, Lampert ML. *Subtherapeutic blood levels of phenytoin due to a medication error*. Praxis (Bern 1994). 2007 Apr 25;96(17):687-92. German.
8. Khanlari B, **Burri E**, Mihatsch F, Flückiger U, Battegay M. *Mycobacterium avium pneumonia in an HIV negative patient*. Internist (Berl). 2007 May;48(5):527-31. German.
9. **Burri E**, Duwe J, Kull C, Glaser C, Maurer CA. *Pulmonary vein thrombosis after lower lobectomy of the left lung*. J Cardiovasc Surg (Torino). 2006 Oct;47(5):609-12.
10. **Burri E**, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R. *Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver*. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):437-41. Review.

# Kantonsspital Baselland

11. **Burri E**, Laffer R, Steuerwald M, Cathomas G, Zimmerli W. *Fever, malaise and new onset mitral valve insufficiency. Subacute Streptococcus bovis mitral valve endocarditis*. Praxis (Bern 1994). 2004 May 5;93(19):819-22. German.
12. **Burri E**, Steuerwald M, Maurer CA, Toia D, Cathomas G, Meier R. *Cystic space-occupying lesion of the liver as an incidental finding. Symptomatic Echinococcus granulosus cyst of the right hepatic lobe*. Praxis (Bern 1994). 2003 May 28;92(22):1051-4. German

## Oral Presentations/Posters

1. Fellay B, Drzewicka M, **Burri E**, Ueberschlag ME, Ritz A, Wieland J, Schneider M. *Quantum Blue® fCAL extended POC user performance evaluation*. Journal of Crohn's and Colitis, Volume 12, Issue supplement\_1, 16 January 2018, Page S498-S499. Poster presentation UEGW 2017.
2. Fellay B, Kopertowska-Majchrzak M, **Burri E**, Ueberschlag ME, Ritz A, Schuster T. *Quantum Blue® infliximab POC user performance evaluation*. Journal of Crohn's and Colitis 12(supplement\_1):S499. Poster presentation UEGW 2017.
3. Vavricka S, Heinrich H, Misselwitz B, Buetfikofer S, **Burri E**, Rogler G, Breitenmoser F, Schneider X, Zeitz J, Biedermann L, Sauter M. *Ingestion of 100ml and 300ml blood mimicking upper gi bleeding leads to significant calprotectin elevation in healthy volunteers - results from the "Vampire study"*. Journal of Crohn's and Colitis, Volume 11, Issue suppl\_1, 1 February 2017, Pages S142-S143. Poster presentation UEGW 2016.
4. **Burri E**, Meuli N, Beglinger C. *Diagnostic value of fecal calprotectin to detect small bowel pathology in patients with previous negative endoscopy*. Oral presentation UEGW 2014.
5. **Burri E**, Meuli N, Beglinger C. *Diagnostic value of fecal calprotectin to detect small bowel pathology in patients with previous negative endoscopy*. Oral presentation SGG 2014.
6. Barba E, **Burri E**, Accarino A, Quiroga S, Monclus E, Navazo I, Malagelada JR, Azpiroz F. *Origin of abdominal distension: is it in the chest after all?* Oral presentation UEGW 2013.
7. **Burri E**, Barba E, Hernandez C, Cisternas D, Accarino A, Malagelada JR. *Abdominal bloating is associated to abdomino-phrenic dyssynergia*. Oral presentation UEGW 2012.
8. **Burri E**, Niederberger C, Beglinger C. *Calprotectin measurement in ascitic fluid: a new test for the rapid diagnosis of spontaneous bacterial peritonitis*. Oral presentation SGG 2011.
9. **Burri E**, Accarino A, Azpiroz F. *Bloating and distension in functional gastrointestinal disorders results from abdomino-phrenic muscle dyssynergia*. Poster presentation SGG 2011.
10. **Burri E**, Huaman W, Hernandez C, Accarino A, Malagelada JR, Azpiroz F. *Abdomino-phrenic dyssynergia in patients with functional dyspepsia*. Oral presentation UEGW 2011.
11. **Burri E**, Niederberger C, Beglinger C. *Calprotectin measurement in ascitic fluid: a new test for the rapid diagnosis of spontaneous bacterial peritonitis*. Oral presentation UEGW 2011.
12. **Burri E**, Azpiroz F, Cisternas D, Accarino A, Malagelada JR. *Abdominal accommodation: specific response to upper gut filling*. Oral presentation UEGW 2010.
13. **Burri E**, Azpiroz F, Hernandez C, Hernandez C, Accarino A, Malagelada JR. *Biofeedback treatment of abdominal distension: a proof-of-concept*. Poster presentation UEGW 2010.
14. **Burri E**, Potocki M, Schütz P, Eriksson U, Taegtmeier A, Niederhauser N, Noveanu M, Breithardt T, Schaub N, Reichlin T, Müller C. *Diagnostic and prognostic value of arterial blood gas analysis in patients with acute dyspnea*. Poster presentation SGIM 2009.
15. Manz M, **Burri E**, Niederberger C, Rothen C, Beglinger C. *Faecal calprotectin predicts upper gastrointestinal pathology*. Poster presentation UEGW 2009.
16. **Burri E**, Meier R. *Nutritional assessment and nutritional intervention in medical in-patients*. Poster presentation ESPEN 2006.
17. Duwe J, **Burri E**, Toia D, Nussbaumer P, Maurer CA. *Embolization of a high-output aortocaval fistula: an endovascular transfemoral bidirectional approach*. Poster presentation SGC 2004.
18. **Burri E**, Duwe J, Abitabile P, Cathomas G, Maurer CA. *Fibrolamellar Carcinoma in a Male Caucasian*. Oral presentation SGC 2004.
19. **Burri E**, Duwe J, Kocher M, Kull C, Maurer CA. *Pulmonary Vein Thrombosis after Lobectomy*. Oral presentation SGC 2004.

# Kantonsspital Baselland

20. **Burri E**, Antoniou E, Drewe J, Meier R. *The effect of different proton pump inhibitors on gastric acidity in volunteers on the first and third day of treatment*. Poster presentation UEGW 2003.
21. **Burri E**, Glaser C, Cathomas G, Maurer CA. *Adenoma of the ampulla vateri: a cause for secondary biliary cirrhosis*. Oral presentation SGC 2003.

## Academic Activity

### Research

- Mechanisms of gastro-esophageal and laryngo-pharyngeal reflux disease - Development and validation of new diagnostic algorithms and comparison of different diagnostic tools.
- Mechanisms of bloating and distension in patients with functional gastrointestinal disorders (irritable bowel syndrome or functional dyspepsia) - the role of thoraco-abdominal muscular dyssynergia.
- The value of non-invasive inflammatory fecal markers in the diagnosis of organic intestinal disease - Appropriate use of endoscopic investigations.
- Diagnosis and surveillance of Inflammatory Bowel Disease with non-invasive inflammatory fecal marker - Optimizing medical treatment and improving disease outcome.
- Bed-side testing for infectious complications from liver cirrhosis - Calprotectin in ascites as biomarker for spontaneous bacterial peritonitis.

### Teaching

- Lectures for medical students, University of Basel, Switzerland (since 2015)
- Instructor of clinical courses for Clinical Nursing Science, University of Basel, Switzerland (since 2014)
- Supervision of several MD and Bachelor theses and at the University of Basel, Switzerland (since 2008)
- Instructor of clinical courses for MD students in Internal Medicine, University of Basel, Switzerland (since 2007)
- Examiner for MD students: OSCE (Objective Structured Clinical Examination), University of Basel, Switzerland (2008)
- Instructor of MD courses in histopathology, Department of Histology, University of Fribourg, Switzerland (1996)